JACC-Heart Failure

Papers
(The H4-Index of JACC-Heart Failure is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Call for Fine Remote Monitoring of Prognostic Signs and Symptoms in Heart Failure204
Everything I Wanted163
Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure152
Guideline-Recommended Therapy Following Hospitalization for Heart Failure137
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status111
Opportunities for Change in Home Health Care in Heart Failure93
Topping Off the Pill Box88
Blood Volume Analysis-Guided Heart Failure Management84
Immune Checkpoint Inhibitors Myocarditis80
The EVOLVeD Role of Cholesterol-Lowering Therapies in Cardiac Allograft Vasculopathy72
Simplifying Treatment of Congestion70
Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum66
Wearable Remote Patient Monitoring Devices64
Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock60
Donor Selection for Heart Transplantation in 202556
Heart Transplant and Pregnancy56
Atrial Fibrillation and Heart Failure55
Desire for Prognostic Information Among Persons With Advanced Heart Failure55
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit52
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF51
Advanced Cardiovascular Imaging in Clinical Heart Failure50
Accepting the Pulmonary Artery Catheter for Cardiogenic Shock48
How to Skydive Without a Parachute47
Officers Page45
Metabolic Risk Score in Heart Failure44
Full Issue PDF44
Table of Contents44
The Advanced Heart Failure and Transplant Cardiology Fellowships Match42
Shifting the Paradigm of Risk From Resting to Exercise-Induced Blood Pressure Changes in HFpEF41
Pharmacologic Heart Rate Modulation in Heart Failure With Preserved Ejection Fraction40
Expenditure on Heart Failure in the United States40
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies39
Clinical Predictors of Referral for and Yield of Genetic Testing in Peripartum Cardiomyopathy39
Insights From the History and Physical Examination in HFpEF or HFrEF39
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk38
Cardiac Resynchronization Therapy in Ischemic Versus Nonischemic Cardiomyopathy37
The Evaluation of Digital Technologies for Heart Failure Management37
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation37
0.19612312316895